TRK Inhibitors: A Tumor Agnostic Approach to Treatment of Solid Tumors

For Melanoma and Skin Cancer Awareness Month, Nayoung Lee, MD, discussed evolving paradigms in skin cancer diagnosis and prevention.

In this episode of Emerging Experts, Michael LaPelusa, MD, shares his insights, experiences, and passion for cancer research, particularly in the realm of gastrointestinal cancers.

The phase 3 KeyVibe-010 study will discontinue the coformulation of pembrolizumab and vibostolimab treatment for high-risk melanoma due to futility.

In this episode of Emerging Experts, Nazli Dizman, MD, shares the intricacies of her journey towards becoming an oncologist in the United States.

In an interview with Targeted Oncology for Brain Cancer Awareness Month, Theodore Schwartz, MD, discussed the challenges of targeting brain tumors, emerging therapies, and strategies to overcome the blood-brain barrier.

Training at a major academic center offers firsthand exposure to groundbreaking 177Lu-PSMA-617 treatment for advanced prostate cancer.